A share price of Transmedics Group Inc [TMDX] is currently trading at $69.09, up 3.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 10.37% over the last week, with a monthly amount drifted -3.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
Transmedics Group Inc experienced fluctuations in its stock price throughout the past year between $58.27 and $177.37. Currently, Wall Street analysts expect the stock to reach $116.33 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $69.09 at the most recent close of the market. An investor can expect a potential return of 68.37% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 401.09M which represents 63.72% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.93 points at the first support level, and at 64.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 71.18, and for the 2nd resistance point, it is at 73.26.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 8.20. Also, the Quick Ratio is 7.33, while the Cash Ratio stands at 5.5. Considering the valuation of this stock, the price to sales ratio is 6.01, the price to book ratio is 11.05 and price to earnings (TTM) ratio is 74.02.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Dec 02 ’24 when 1084.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Nov 11 ’24 to sell 1458.0 shares. Meanwhile, Director Basile Edward M sold 6750.0 shares on Nov 05 ’24.
